H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Century Therapeutics to $13 from $17 and keeps a Buy rating on the shares post the Q2 report. The company’s “strong” balance sheet extends its runway through key catalysts, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IPSC: